Renal Function
Conditions
Brief summary
This study designed a over-knee automatic step counter device. Then, we evaluated its efficacy on renal function and oxidative stress in patients with chronic kidney disease.
Detailed description
This study is a randomized controlled trial. Patients who consent to participate and pass the screening process will be randomly assigned to groups based on the order of their participation (random by sequence). Patients who join in odd-numbered order, such as 1st, 3rd, 5th, etc., will receive standard care as provided by the hospital (control group). Patients who join in even-numbered order, such as 2nd, 4th, 6th, etc., will receive a walking program. This involves continuous walking exercise for 30 minutes, once a day, three days a week, over a period of three months. During the walking sessions, patients will walk at a pace of 60 steps per minute, or one step per second.
Interventions
OTHERRhythmic walking
Patients who consent to participate and pass the screening process were randomly assigned to groups based on the order of their participation (random by sequence): control group or rhythmic walking group.
Sponsors
Burapha University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
Outcome assessors were blinded to the intervention administered to each patient.
Intervention model description
This study is a randomized controlled trial. Patients who consent to participate and pass the screening process will be randomly assigned to groups based on the order of their participation (random by sequence). Patients who join in odd-numbered order, such as 1st, 3rd, 5th, etc., will receive standard care as provided by the hospital (control group). Patients who join in even-numbered order, such as 2nd, 4th, 6th, etc., will receive a walking program.
Eligibility
Sex/Gender
ALL
Age
18 Years to 59 Years
Healthy volunteers
No
Inclusion criteria
* Male or female * Aged between 18 and 59 years * Diagnosed by a physician with chronic kidney disease stage 2-4, with a glomerular filtration rate (GFR) between 15-89 milliliters per minute, persisting for at least 3 months
Exclusion criteria
* No musculoskeletal disorders that hinder walking, such as osteoarthritis * Not engaging in regular exercise (less than 3 times per week or less than 150 minutes per week) * Not regularly taking medications or supplements containing antioxidants
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Creatinine level | Day 0 and day 91 | Blood creatinine level was measured in mg/dL unit |
| Malondialdehyde level | Day 0 and day 91 | Blood malondialdehyde level was measured in micromolar unit |
| Superoxide dismutase activity level | Day 0 and day 91 | Blood superoxide dismutase activity level was measured in percent unit |
| Estimated glomerular filtration rate level | Day 0 and day 91 | Estimated glomerular filtration rate level was measured in ml/min/1.73 m2 unit |
| Estimated creatinine clearance level | Day 0 and day 91 | Estimated creatinine clearance level was measured in ml/min unit |
Countries
Thailand
Outcome results
None listed